PBM Disclosure Requirements On Rx Switches Likely To Increase Costs – FTC
Executive Summary
Pharmaceutical benefit manager disclosure requirements related to drug switches are likely to increase consumers' drug costs rather than strengthen consumer protections, the Federal Trade Commission said in its review of PBM transparency legislation under consideration in California